Promoted Content Promoted Content


Find Clinical Drug Development Pipelines & Deals | PipelineProspector


All Data

Filters Filter refresh
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): KHK4083

            Therapeutic Area: Dermatology Product Name: KHK4083

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Amgen Inc

            Deal Size: $1,250.0 million Upfront Cash: $400.0 million

            Deal Type: Collaboration June 01, 2021


            KHK4083 is an anti-OX40 fully human monoclonal antibody discovered by Kyowa Kirin and engineered with Kyowa Kirin’s patented POTELLIGENT® defucosylation technology to enhance its antibody-dependent cellular cytotoxicity (ADCC) activity.